Scarica l'app Stockscreener
11.87
1.16%
0.1358
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché EVH Giù?
Forum
Previsione
Precedente Chiudi:
$11.73
Aprire:
$11.81
Volume 24 ore:
1.26M
Relative Volume:
0.60
Capitalizzazione di mercato:
$1.05B
Reddito:
$2.35B
Utile/perdita netta:
$-74.42M
Rapporto P/E:
-12.62
EPS:
-0.94
Flusso di cassa netto:
$150.93M
1 W Prestazione:
+10.38%
1M Prestazione:
+38.78%
6M Prestazione:
-0.12%
1 anno Prestazione:
-39.89%
Intervallo 1D:
$11.61
$11.92
Intervallo di 1 settimana:
$10.54
$11.92
Portata 52W:
$7.06
$33.48
Evolent Health Inc Stock (EVH) Company Profile
Nome
Evolent Health Inc
Settore
Industria
Telefono
571-389-6000
Indirizzo
1812 NORTH MOORE ST, SUITE 1705, ARLINGTON
Confronta EVH con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EVH
Evolent Health Inc
|
11.87 | 1.05B | 2.35B | -74.42M | 150.93M | -0.94 |
|
VEEV
Veeva Systems Inc
|
284.29 | 46.43B | 2.86B | 780.66M | 1.20B | 4.72 |
|
TEM
Tempus Ai Inc
|
60.97 | 12.01B | 803.32M | -709.10M | -212.68M | -7.8003 |
|
DOCS
Doximity Inc
|
61.00 | 10.79B | 550.17M | 201.35M | 232.07M | 1.00 |
|
HQY
Healthequity Inc
|
102.16 | 9.27B | 1.15B | 96.70M | -161.99M | 1.09 |
|
WAY
Waystar Holding Corp
|
39.34 | 7.03B | 906.14M | -52.62M | 89.62M | -0.3621 |
Evolent Health Inc Stock (EVH) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-01-10 | Iniziato | Needham | Buy |
| 2024-12-03 | Reiterato | BTIG Research | Buy |
| 2024-11-08 | Downgrade | Stephens | Overweight → Equal-Weight |
| 2024-10-11 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2024-08-09 | Aggiornamento | Truist | Hold → Buy |
| 2024-04-22 | Iniziato | Citigroup | Buy |
| 2024-03-01 | Iniziato | Oppenheimer | Outperform |
| 2024-01-03 | Iniziato | Barclays | Overweight |
| 2023-12-06 | Iniziato | JMP Securities | Mkt Outperform |
| 2023-10-16 | Iniziato | UBS | Buy |
| 2023-04-12 | Iniziato | Stephens | Overweight |
| 2022-11-01 | Iniziato | Truist | Hold |
| 2022-07-29 | Iniziato | RBC Capital Mkts | Outperform |
| 2022-03-30 | Iniziato | Guggenheim | Buy |
| 2021-11-18 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-04-29 | Ripresa | JP Morgan | Neutral |
| 2021-01-07 | Iniziato | BTIG Research | Buy |
| 2020-07-06 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2020-06-05 | Downgrade | Goldman | Buy → Neutral |
| 2020-06-02 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2018-10-05 | Ripresa | Leerink Partners | Outperform |
| 2018-06-04 | Iniziato | Piper Jaffray | Overweight |
| 2018-04-24 | Ripresa | JP Morgan | Neutral |
| 2017-09-20 | Iniziato | KeyBanc Capital Mkts | Overweight |
| 2017-06-02 | Iniziato | Robert W. Baird | Outperform |
| 2017-03-14 | Iniziato | Oppenheimer | Outperform |
| 2017-01-13 | Aggiornamento | Wells Fargo | Market Perform → Outperform |
| 2016-10-28 | Ripresa | JP Morgan | Overweight |
| 2016-08-05 | Reiterato | FBR Capital | Outperform |
| 2016-07-26 | Iniziato | Jefferies | Buy |
| 2016-07-13 | Reiterato | FBR Capital | Outperform |
| 2016-03-29 | Iniziato | FBR Capital | Outperform |
| 2016-01-06 | Iniziato | Canaccord Genuity | Buy |
| 2015-06-30 | Iniziato | Goldman | Buy |
| 2015-06-30 | Iniziato | JP Morgan | Overweight |
| 2015-06-30 | Iniziato | Leerink Partners | Outperform |
| 2015-06-30 | Iniziato | Sun Trust Rbsn Humphrey | Buy |
Mostra tutto
Evolent Health Inc Borsa (EVH) Ultime notizie
EVH Q1 Earnings Call: Oncology Navigation Launch and AI Automation Drive Strategic Focus - Yahoo Finance
Evolent Health, Inc. Appoints Shawn Guertin to the Board of Directors and Reconstitutes Compositions of Committees, Effective June 5, 2025 - marketscreener.com
3 Stocks Under $10 in the Doghouse - Yahoo Finance
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Evolent Health, Inc. To Contact The Firm - ACCESS Newswire
Evolent Health at William Blair Conference: Strategic Growth Amid Challenges - Investing.com Australia
Evolent Health Reaffirms 2025 Revenue and EBITDA Guidance - TipRanks
Evolent HealthReaffirms 2025 Revenue Guidance Of $2.06 Bln To $2.11 BlnSEC Filing - marketscreener.com
Why Investors Shouldn't Be Surprised By Evolent Health, Inc.'s (NYSE:EVH) 25% Share Price Plunge - simplywall.st
Evolent Health, Amphastar Pharmaceuticals, Iridium, and Magnite Stocks Trade Up, What You Need To Know - Yahoo Finance
Evolent Health’s SWOT analysis: value-based care provider faces challenges, opportunities - Investing.com Australia
Evolent Health’s SWOT analysis: value-based care provider faces challenges, opportunities By Investing.com - Investing.com South Africa
Evolent Health, Inc. (NYSE:EVH) Given Average Recommendation of “Buy” by Analysts - Defense World
Deutsche Bank AG Raises Holdings in Evolent Health, Inc. (NYSE:EVH) - Defense World
Trend Tracker for (EVH) - news.stocktradersdaily.com
Reflecting On Healthcare Technology for Providers Stocks’ Q1 Earnings: Evolent Health (NYSE:EVH) - Yahoo Finance
Evolent Health stock hits 52-week low at $8.35 By Investing.com - Investing.com South Africa
Guardant Health, Evolent Health, Charles River Laboratories, Avantor, and Lumen Stocks Trade Down, What You Need To Know - Yahoo Finance
Evolent Health stock hits 52-week low at $8.35 - Investing.com Australia
Comerica Bank Has $69,000 Holdings in Evolent Health, Inc. (NYSE:EVH) - Defense World
Needham & Company LLC Reiterates Buy Rating for Evolent Health (NYSE:EVH) - Defense World
Evolent Health (EVH) Sees Analyst Reaffirm Buy Rating and $15 Pr - GuruFocus
Evolent Health (EVH) Sees Analyst Reaffirm Buy Rating and $15 Price Target | EVH Stock News - GuruFocus
Evolent Health (NYSE:EVH) Price Target Raised to $15.00 - Defense World
Evolent Health (NYSE:EVH shareholders incur further losses as stock declines 15% this week, taking three-year losses to 68% - simplywall.st
Evolent Health (EVH) Receives Price Target Upgrade from UBS | EV - GuruFocus
Evolent Health, Inc. (NYSE:EVH) Q1 2025 Earnings Call Transcript - Insider Monkey
Analysts Have Conflicting Sentiments on These Healthcare Companies: Evolent Health (EVH), Verastem (VSTM) and Sight Sciences (SGHT) - The Globe and Mail
Evolent Health Inc. Earnings Call Highlights Growth and Expansion - TipRanks
Expert Outlook: Evolent Health Through The Eyes Of 9 Analysts - Benzinga
Evolent Health (EVH) Receives Price Target Upgrade from UBS | EVH Stock News - GuruFocus
Evolent Health (EVH) Reports Q1 Earnings: What Key Metrics Have to Say - Yahoo Finance
Evolent Health Q1 2025 slides: Revenue falls but company maintains full-year guidance - Investing.com Australia
UBS Adjusts Price Target on Evolent Health to $15 From $14, Maintains Buy Rating - marketscreener.com
Evolent Health (EVH) Receives Price Target Boost from UBS | EVH Stock News - GuruFocus
Evolent Health Surpasses Revenue Expectations Despite Sales Decline - IndexBox
Evolent Health Inc earnings missed by $0.02, revenue topped estimates - Investing.com India
Evolent Health, Inc. SEC 10-Q Report - TradingView
Evolent Health Inc (EVH) Q1 2025 Earnings Call Highlights: Strong Start with New Agreements and ... By GuruFocus - Investing.com Canada
Evolent Health Inc (EVH) Q1 2025 Earnings Call Highlights: Strong Start with New Agreements and ... - Yahoo Finance
Evolent Health Inc (EVH) Q1 2025 Earnings Call Highlights: Strong Start with New Agreements and AI Advancements - GuruFocus
Earnings call transcript: Evolent Health Q1 2025 misses EPS forecast, stock rises - Investing.com
Evolent Health: Q1 Earnings Snapshot - Norwalk Hour
Evolent Health Reports Strong Q1 2025 Growth - TipRanks
Evolent Health Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Evolent Health (EVH) Q1 Earnings Lag Estimates - Yahoo Finance
Evolent Health (NYSE:EVH) Posts Better-Than-Expected Sales In Q1, Full-Year Outlook Slightly Exceeds Expectations - Yahoo Finance
Evolent Health Inc Azioni (EVH) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Evolent Health Inc Azioni (EVH) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| McCarthy Daniel Joseph | PRESIDENT |
Mar 06 '25 |
Buy |
9.01 |
11,040 |
99,470 |
389,004 |
| Jelinek Richard M | Director |
Mar 07 '25 |
Buy |
9.12 |
30,000 |
273,750 |
15,000 |
| GRUA PETER J | Director |
Mar 06 '25 |
Buy |
9.01 |
11,040 |
99,470 |
18,749 |
| Blackley Seth | Chief Executive Officer |
Mar 06 '25 |
Buy |
9.01 |
55,225 |
497,577 |
762,217 |
| Springstubb Brendan B | Director |
Mar 07 '25 |
Buy |
9.27 |
15,000 |
139,050 |
26,842 |
| Glass Russell Monroe | Director |
Mar 06 '25 |
Buy |
9.27 |
5,400 |
50,058 |
14,272 |
| KECK KIM | Director |
Mar 07 '25 |
Buy |
9.44 |
10,540 |
99,498 |
39,522 |
| Barbarosh Craig A. | Director |
Mar 06 '25 |
Buy |
8.81 |
2,000 |
17,620 |
31,956 |
| Springstubb Brendan B | Director |
Mar 04 '25 |
Buy |
8.75 |
5,000 |
43,750 |
11,842 |
0.62%
1.39%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):